N-Methyl-heptamethylenimin | 19719-81-4

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: N-Methyl-heptamethylenimin
• 英文别名: 1-Methyloctahydroazocine；1-methylazocane
• CAS: 19719-81-4
• 化学式: C₈H₁₇N
• mdl: MFCD25960644
• 分子量: 127.23
• InChiKey: CAROGVXIVVOPKA-UHFFFAOYSA-N

物化性质

• 沸点：
  162-163 °C(Press: 746 Torr)
• 密度：
  0.8558 g/cm3(Temp: 21 °C)
• 保留指数：
  970

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  9
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  3.2
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  N-Methyl-heptamethylenimin 在 platinum(IV) oxide 氢气 作用下， 以 溶剂黄146 为溶剂， 生成 N-甲基庚胺
  参考文献：
  名称：

  Amine Oxides. VII. The Thermal Decomposition of the N-Oxides of N-Methylazacycloalkanes^1,2

  摘要：

  Ring cleavage of the N-oxides of N-methylazacycloalkanes by a thermal elimination reaction does not occur when the ring is six-membered and becontes progressively easier as the ring size is increased from seven to eight atoms. N-Methylpiperidine oxide gave no product from a cis beta-elimination reaction, while pyrolysis of the homologous N-methylhexamethyleneimine and N-methylheptamethyleneimine oxides led to the unsaturated hydroxylamines in yields of 53 and 79%, respectively. These results support a planar five-membered transition state for the amine oxide pyrolysis. The unsaturated hydroxylamines were converted to unsaturated and saturated secondary amines. The thermal decomposition of a mixture of he cis and trans isomers of N-methyl-alpha-pipecoline oxide formed the expected N-methyl-N-5-hexenylhydroxylamine as well as a saturated bicyclic product, formulated as cis-N-methyl-3-oxa-2-azabicyclo [3.3.01 octane. A possible mechanism for the formation of this product is presented. The cis and trans isomers of N-methyl-a-pipecoline oxide have been separated and characterized. Each Of the isomers has been pyrolyzed separately and only trans-N-methyl-a-pipecoline oxide formed the expected unsaturated hydroxylamine.

  DOI：

  10.1021/ja01502a052
• 作为产物：
  描述：

  七亚甲基亚胺 在 lithium aluminium tetrahydride 、 乙醚 、 氯仿 作用下， 生成 N-Methyl-heptamethylenimin
  参考文献：
  名称：

  The Preparation of Basic Alcohols and Basic Alkyl Chlorides which Contain a 1-Hexa-,1-Hepta- or 1-Octamethylenimino Radical

  摘要：

  DOI：

  10.1021/ja01638a011

文献信息

• Novel pyridine derivative and pyrimidine derivative
  申请人：Matsushima Tomohiro

  公开号：US20050277652A1

  公开（公告）日：2005-12-15

  A compound represented by the following formula, a salt thereof or a hydrate of the foregoing has an excellent hepatocyte growth factor receptor (HGFR) inhibitory activity, and exhibits anti-tumor activity, angiogenesis inhibitory activity and cancer metastasis inhibitory activity. [R 1 represents C 1-6 alkyl or the like; R 2 and R 3 represent hydrogen; R 4 , R 5 , R 6 , and R 7 may be the same or different and each represents hydrogen, halogen, C 1-6 alkyl or the like; R 8 represents hydrogen or the like; R 9 represents C 1-6 alkyl or the like; V 1 represents oxygen or the like; V 2 represents oxygen or sulfur; W represents —NH— or the like; X represents —CH═, nitrogen or the like; and Y represents oxygen or the like.]

  以下化合物的分子式，其盐或前述水合物具有出色的肝细胞生长因子受体（HGFR）抑制活性，并表现出抗肿瘤活性、抑制血管生成活性和抑制癌转移活性。 [R 1 代表C 1-6 烷基或类似物；R 2 和R 3 代表氢；R 4 ，R 5 ，R 6 和R 7 可以相同也可以不同，每个代表氢、卤素、C 1-6 烷基或类似物；R 8 代表氢或类似物；R 9 代表C 1-6 烷基或类似物；V 1 代表氧或类似物；V 2 代表氧或硫；W代表—NH—或类似物；X代表—CH═、氮或类似物；Y代表氧或类似物。]
• CARBALDEHYDE OXIMES AS BUTYRYLCHOLINESTERASE REACTIVATORS
  申请人：Etat Français représenté par la Direction Centrale Du Service de Santé des Armées

  公开号：EP3945092A1

  公开（公告）日：2022-02-02

  The present invention relates to compounds for their use in the reactivation of butyrylcholinesterase. Such compounds are useful in the treatment or prevention of the intoxication with at least one organophosphorus nerve agent. The invention also relates to pharmaceutical compositions and kits comprising said compounds, and compounds per se.

  本发明涉及化合物，用于重新激活丁酰胆碱酯酶。这些化合物在治疗或预防至少一种有机磷神经毒剂中毒方面是有用的。该发明还涉及包含所述化合物的药物组合物和试剂盒，以及化合物本身。
• COLORING CURABLE RESIN COMPOSITION, CURED FILM, COLOR FILTER, METHOD FOR MANUFACTURING COLOR FILTER, SOLID-STATE IMAGING DEVICE, IMAGE DISPLAY DEVICE, COMPOUND, AND CATION
  申请人：FUJIFILM Corporation

  公开号：US20160376234A1

  公开（公告）日：2016-12-29

  The present invention provides a colored curable resin composition that exhibits good heat resistance and durability in a sputtering process, a cured film, a color filter, a method for manufacturing a color filter, a solid-state image device, an image display device, a compound, and a cation. The colored curable resin composition contains a colorant represented by Formula (1), Formula (2), or Formula (3), a resin, a polymerizable compound, and a polymerization initiator. In Formula (1), R 101 and R 102 each independently represent a hydrogen atom or a substituent, R 103 to R 106 each independently represent a hydrogen atom, an alkyl group, an aryl group, or a heteroaryl group, R 107 to R 111 each independently represent a hydrogen atom or a substituent, n1 to n4 each independently represent an integer of 0 to 4, n5 represents an integer of 0 to 6, X represents an anion or is not present, and at least one of R 101 , . . . , or R 111 includes an anion; and in the case where R 101 and R 102 represent hydrogen atoms, R 103 represents an aryl group having a substituent at at least the ortho-position.

  本发明提供了一种在溅射工艺中具有良好耐热性和耐久性的着色可固化树脂组合物、固化膜、色滤光器、制造色滤光器的方法、固态图像设备、图像显示设备、化合物和阳离子。该着色可固化树脂组合物含有由公式(1)、公式(2)或公式(3)表示的着色剂、树脂、可聚合化合物和聚合引发剂。在公式(1)中，R101和R102各自独立地表示氢原子或取代基，R103至R106各自独立地表示氢原子、烷基、芳基或杂芳基，R107至R111各自独立地表示氢原子或取代基，n1至n4各自独立地表示0至4的整数，n5表示0至6的整数，X表示阴离子或不出现，且至少R101、…或R111中包括阴离子；且在R101和R102表示氢原子的情况下，R103表示在至少邻位具有取代基的芳基。
• TREATMENT OF DISEASES BY EPIGENETIC REGULATION
  申请人：McLure Kevin G.

  公开号：US20130281399A1

  公开（公告）日：2013-10-24

  The present disclosure provides non-naturally occurring polyphenol compounds that inhibit the bromodomain and extra terminal domain (BET) proteins. The disclosed compositions and methods can be used for treatment and prevention of diseases or disorders that are susceptible to administration of a BET inhibitor.

  本公开提供了抑制溴结构域和额外末端结构域（BET）蛋白的非天然存在的多酚化合物。所公开的组合物和方法可用于治疗和预防对BET抑制剂易感的疾病或疾病。
• HETEROCYCLIC COMPOUND
  申请人：TAKEDA PHARMACEUTICAL COMPANY LIMITED

  公开号：US20160159773A1

  公开（公告）日：2016-06-09

  The present invention provides an agent for the prophylaxis or treatment of autoimmune diseases (e.g., psoriasis, rheumatoid arthritis, inflammatory bowel disease, Sjogren's syndrome, Behcet's disease, multiple sclerosis, systemic lupus erythematosus etc.) and the like, which has a superior Tyk2 inhibitory action. The present invention relates to a compound represented by the formula wherein each symbol is as defined in the specification, or a salt thereof.

  本发明提供了一种用于预防或治疗自身免疫性疾病（例如牛皮癣、类风湿关节炎、炎症性肠病、干燥综合征、贝赫切特病、多发性硬化症、系统性红斑狼疮等）等的药剂，其具有优越的Tyk2抑制作用。 本发明涉及一种由下式表示的化合物 其中每个符号如规范中定义的，或其盐。